Literature DB >> 8363393

In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs.

N Rastogi1, K S Goh, A Bryskier.   

Abstract

The antimycobacterial spectrum of roxithromycin, a semisynthetic 14-membered ring macrolide, was determined against 28 strains belonging to 16 species of atypical mycobacteria by measuring radiometric MICs by BACTEC methodology at two different pH values, i.e., 6.8 and 7.4. The MICs obtained at pH 7.4 were 1 to 2 dilutions lower or more than those obtained at pH 6.8 for some of the species. Roxithromycin possessed promising MICs against such potential pathogens as the Mycobacterium avium complex, M. scrofulaceum, M. szulgai, M. malmoense, M. xenopi, M. marinum, M. kansasii, and rare pathogens like M. chelonei subsp. chelonei and M. chelonei subsp. abscessus but not against M. simiae. Roxithromycin showed lower MICs against M. fortuitum var. peregrinum than M. fortuitum var. fortuitum.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8363393      PMCID： PMC188015          DOI： 10.1128/AAC.37.7.1560

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium.

Authors:  L B Heifets; P J Lindholm-Levy; R D Comstock
Journal:  Am Rev Respir Dis       Date:  1992-04

Review 5.  Intracellular distribution and activity of antibiotics.

Authors:  P M Tulkens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

6.  Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin.

Authors:  J R Martin; P Johnson; M F Miller
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  In vitro susceptibility of Mycobacterium avium to a new macrolide (RU-28965).

Authors:  M Casal; F Rodriguez; R Villalba
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

Review 9.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

10.  [In vitro sensitivity of Mycobacterium avium and Mycobacterium xenopi to erythromycin, roxithromycin and doxycycline].

Authors:  J Maugein; J Fourche; M Mormede; J L Pellegrin
Journal:  Pathol Biol (Paris)       Date:  1989-06
View more
  11 in total

1.  Lesser known mycobacteria.

Authors:  B Watt
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

Review 2.  Intracellular concentrations of antibacterial agents and related clinical implications.

Authors:  J D Butts
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

3.  Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.

Authors:  N Rastogi; K S Goh; A Bryskier; A Devallois
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.

Authors:  L E Bermudez; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

5.  Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.

Authors:  N Rastogi; K S Goh; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages.

Authors:  N Rastogi; V Labrousse; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

7.  Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice.

Authors:  L Struillou; Y Cohen; N Lounis; G Bertrand; J Grosset; J L Vildé; J J Pocidalo; C Perronne
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

8.  Potential role of roxithromycin against the Mycobacterium avium complex.

Authors:  L S Young; L E Bermudez; M Wu; C B Inderlied
Journal:  Infection       Date:  1995       Impact factor: 3.553

9.  In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex.

Authors:  N Rastogi; K S Goh; P Ruiz; M Casal
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

Review 10.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.